Leerink analyst David Risinger upgraded AbbVie (ABBV) to Outperform from Market Perform with a $206 price target The firm recommends taking advantage of the emraclidine setback and election-related downdraft to purchase shares, and tells investors in a research note that while its financial projections are roughly in line with consensus, but Leerink sees the potential for continued strong execution to drive upside, including for Skyrizi in its recently-launched ulcerative colitis indication. While Leerink believes AbbVie overpaid for Cerevel and will likely have to take a significant emraclidine write-down in early 2025, the firm continues to view the company as having strong leadership with good judgment, and says other Cerevel assets could generate positive Phase 2 results in coming years, and the company could execute additional M&A which enhances its growth prospects.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABBV:
- AbbVie upgraded to Outperform from Market Perform at Leerink
- 3 Best Stocks to Buy Now, 11/19/2024, According to Top Analysts
- AbbVie receives EC approval of Elahere
- Wolfe starts AbbVie at Outperform, says valuation an attractive entry point
- AbbVie initiated with an Outperform at Wolfe Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
